Interplay between cancer cells, macrophages and natural killer cells may actually decide the outcome of therapy with sorafenib

Authors

  • Ciprian Tomuleasa M.D., Ph.D.,

    1. Center for Functional Genomics and Translational Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania
    2. Department of Hematology, Ion Chiricuta Comprehensive Cancer Center, Cluj Napoca, Romania
    Search for more papers by this author
  • Gianluigi Giannelli M.D., Ph.D.,

    1. Department of Internal Medicine, Immunology and Infectious Diseases, Section of Internal Medicine, University of Bari Medical School, Bari, Italy
    Search for more papers by this author
  • Andrei Cucuianu M.D., Ph.D.,

    1. Department of Hematology, Ion Chiricuta Comprehensive Cancer Center, Cluj Napoca, Romania
    Search for more papers by this author
  • Mihaela Aldea M.D.,

    1. Center for Functional Genomics and Translational Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania
    Search for more papers by this author
  • Angelo Paradiso M.D., Ph.D.,

    1. Clinical Experimental Oncology Laboratory, National Cancer Institute Giovanni Paolo II, Bari, Italy
    Search for more papers by this author
  • Ioana Berindan-Neagoe Ph.D.

    1. Center for Functional Genomics and Translational Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania
    Search for more papers by this author

  • Potential conflict of interest: Nothing to report.

No abstract is available for this article.

Ancillary